 Crinetics Pharmaceuticals NASDAQ:CRNX was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Monday, Zacks.com reports. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related ... 